------------------------ Yahoo! Groups Sponsor --------------------~-->
Get fast access to your favorite Yahoo! Groups. Make Yahoo! your home page
http://us.click.yahoo.com/dpRU5A/wUILAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

Invitrogen Enters into Worldwide Co-Marketing Agreement with genOway
Focused on RNAi Services; Deal Positions Companies to Address in
vivo Target Validation Market

CARLSBAD, Calif. & LYON, France Dec. 15, 2005--Invitrogen
Corporation (Nasdaq:IVGN), a provider of essential life science
technologies for disease research and drug discovery and genOway, a
creator of genetically modified biological models today announced
the signing of a co-marketing agreement around RNAi related
services. Under the terms of the agreement, Invitrogen and genOway
will combine Invitrogen's expertise in RNAi research technologies
with genOway's portfolio of transgenesis technologies and RNAi in
vivo experience to create a services platform offering RNAi vector
design through the creation of RNAi transgenic rodent models. Both
companies will share revenues but specific financial terms of the
collaboration were not disclosed.

An important part of the drug discovery research and development
process involves in vivo studies, often performed in animal models.
As RNAi technology has advanced, the need to validate RNAi knockdown
in model systems has been regarded as the next step in the eventual
development of therapeutics based on the technique.

"Combining the services of these two leading RNAi companies will
provide researchers with a complete solution to ensure successful
RNAi research for drug discovery and therapeutic applications," said
Jon Hindar, Senior Vice President of Life Sciences at
Invitrogen. "This broad service offering has the potential to
significantly accelerate target validation studies in disease
research."

"RNAi continues to gain acceptance in drug discovery and development
applications," explained Kader Thiam, Head of Transgenic
technologies of genOway. "Our leading in vivo RNAi technologies are
strengthened by the solid in vitro applications Invitrogen has
developed."

RNAi has rapidly become one of the most widely used techniques in
drug discovery research. Using RNAi technology, scientists can turn
genes "off," enabling them to observe a cell's behavior in the
absence of the targeted gene's protein product. This may lead to
better understanding of disease mechanisms and eventually, better
therapies.

Invitrogen has built a strong RNAi technology portfolio in recent
years, first offering a family of products under the BLOCK-iT(TM)
name in September 2003, including short interfering RNA (siRNA),
kits for creating short hairpin RNA (shRNA), and technologies to
deliver RNAi reagents to cells and tissues. In November 2003,
Invitrogen announced that it had acquired privately-held Sequitur,
Inc. of Natick, Mass. Sequitur brought to Invitrogen Stealth(TM)
technology, a proprietary synthetic RNA molecule that holds
advantages over traditional siRNA in specificity, efficacy,
stability and reducing "off target" effects of silencing. Invitrogen
continues to develop technologies to enhance its comprehensive RNAi
solution to address evolving needs of researchers in the formative
era of the application. This year Invitrogen launched the BLOCK-iT
(TM) pol II miR RNAi expression vector kits and services which
combine the advantages of traditional RNAi vectors with capabilities
for tissue specific expression and multiple target knockdown from
the same transcript.

In three years, genOway has become the leading company for in vivo
RNAi rodent models. Beginning in 2003 genOway launched its Safe RNAi
Transgenesis(TM) technology based on random integration of shRNA
into ES cells. In 2004 the company launched its RNAi Quick Knock-in
(TM) technology that allows targeted insertion of the shRNA into a
specific gene locus, HPRT. Most recently genOway has started
offering a Rat Knock-down R&D program.

About genOway

Based in Lyons, France and Hamburg, Germany genOway is a service
provider fully dedicated to the development of tailor made
transgenic mouse and rat models. The company has established
business relationships with renowned academic research centres,
major biotech companies and leading pharmaceuticals companies.
Operating in 20 countries in Europe, North America and Japan,
genOway is, with respect to staff and clients, the largest company
in its field in Europe. For more information, visit www.genoway.com.

About Invitrogen

Invitrogen Corporation (Nasdaq:IVGN) provides products and services
that support academic and government research institutions and
pharmaceutical and biotech companies worldwide in their efforts to
improve the human condition. The company provides essential life
science technologies for disease research, drug discovery, and
commercial bioproduction. Invitrogen's own research and development
efforts are focused on breakthrough innovation in all major areas of
biological discovery including functional genomics, proteomics,
bioinformatics and cell biology - placing Invitrogen's products in
nearly every major laboratory in the world. Founded in 1987,
Invitrogen is headquartered in Carlsbad, California and conducts
business in more than 70 countries around the world. The company
globally employs approximately 4,800 scientists and other
professionals and had revenues of more than $1 billion in 2004. For
more information, visit www.invitrogen.com.

Safe Harbor Statement

Certain statements contained in this press release are
considered "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995, and it is
Invitrogen's intent that such statements be protected by the safe
harbor created thereby. Forward-looking statements include, but are
not limited to: 1) Invitrogen and genOway will combine in vitro and
in vivo applications to form a complete RNAi services platform; 2)
Invitrogen and genOway will share revenues from the co-marketing
agreement; and 3) The collaboration will accelerate target
validation studies in disease research. Such forward-looking
statements are subject to a number of risks, uncertainties and other
factors that could cause actual results to differ materially from
future results expressed or implied by such forward-looking
statements. Potential risks and uncertainties include, but are not
limited to, the risks: a) Details of the agreement are subject to
change according to the evolution of the program; b) Financial terms
of the agreement may vary; and c) The collaboration and co-marketing
agreement may have no significant impact on target validation or
disease research, as well as other risks and uncertainties detailed
from time to time in Invitrogen's Securities and Exchange Commission
filings.

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech